Nexiam I.V. (Esomeprazole)

Esomeprazole, a proton pump inhibitor, is indicated for several acid‑related gastrointestinal conditions.

• Gastro‑esophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation.
• Erosive esophagitis: promotes healing of acid‑induced esophageal lesions.
• Prevention of stress‑related mucosal bleeding: decreases risk of gastrointestinal bleeding in critically ill patients.

• Esomeprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, leading to increased gastric pH and providing gastro‑protective effects. The inhibition persists for up to 72 hours as new enzyme molecules must be synthesized, allowing sustained acid suppression after a single intravenous dose.

Esomeprazole administered intravenously may be associated with a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity, may be transient or persistent during therapy.
• Diarrhea: loose stools, often transient, usually resolves without intervention.
• Injection site reactions: erythema, swelling, or mild pain at the infusion site.

Serious or Rare Side Effects

• Severe hypersensitivity: rash, angioedema, or anaphylaxis requiring immediate medical attention.
• Clostridioides difficile infection: severe colitis with watery diarrhea, fever and abdominal cramping.
• Low magnesium levels (hypomagnesemia): may cause muscle cramps, tremor, or cardiac arrhythmia if untreated.

When using Nexiam I.V., clinicians should observe several precautionary measures to ensure patient safety and product integrity.

• Renal impairment: adjust therapy and monitor renal function, as drug clearance may be reduced.
• Hepatic dysfunction: use cautiously; monitor liver enzymes in patients with severe liver disease.
• Concomitant anticoagulants: increased risk of bleeding; assess coagulation status regularly.
• Elderly patients: higher incidence of adverse effects; consider dose adjustment and close monitoring.
• Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Esomeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Ketoconazole and itraconazole: reduced antifungal absorption; avoid concurrent use.
• Atazanavir: markedly decreased antiviral exposure; contraindicated.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation parameters.
• Digoxin: may increase serum levels; check digoxin concentrations.
• Clopidogrel: reduced activation leading to decreased antiplatelet effect; monitor platelet function.